Get the Stockscreener App
3.19
0.00%
0.00
Akebia Therapeutics Inc stock is traded at $3.19, with a volume of 3.25M.
It is up +0.00% in the last 24 hours and down -17.14% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$3.19
Open:
$3.2
24h Volume:
3.25M
Relative Volume:
0.69
Market Cap:
$845.81M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-11.39
EPS:
-0.28
Net Cash Flow:
$-23.38M
1W Performance:
-1.85%
1M Performance:
-17.14%
6M Performance:
+77.22%
1Y Performance:
+117.01%
1-Day Range:
$3.17
$3.32
1-Week Range:
$3.02
$3.32
52-Week Range:
$1.24
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
3.19 | 824.60M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Resumed | H.C. Wainwright | Buy |
| Apr-28-25 | Initiated | Leerink Partners | Outperform |
| Apr-01-25 | Initiated | Jefferies | Buy |
| Nov-29-23 | Resumed | BTIG Research | Buy |
| Aug-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-31-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-22 | Downgrade | Needham | Buy → Hold |
| Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-19 | Reiterated | Needham | Buy |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
| May-02-19 | Initiated | JP Morgan | Overweight |
| Mar-20-19 | Initiated | Citigroup | Neutral |
| Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-18 | Reiterated | Needham | Buy |
| Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-17 | Initiated | Piper Jaffray | Overweight |
| Dec-07-17 | Initiated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | Needham | Buy |
| Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
| Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-15-16 | Initiated | Aegis Capital | Buy |
| Sep-29-16 | Initiated | Brean Capital | Buy |
| Mar-16-16 | Reiterated | Needham | Buy |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
Akebia Therapeutics (AKBA) Bounces to Profitability amid Kidney Treatment Growth - uk.finance.yahoo.com
Why Akebia Therapeutics Inc. stock attracts strong analyst attentionProfit Target & Daily Growth Stock Tips - beatles.ru
Akebia Therapeutics Inc. Ranks High in Smart Money TrackerPortfolio Return Report & Breakout Confirmation Trade Signals - 선데이타임즈
What makes Akebia Therapeutics Inc. stock price move sharply2025 Key Lessons & Safe Entry Point Alerts - sundaytimes.kr
Akebia Therapeutics Reports Record Revenue and Strategic Growth - The Globe and Mail
Akebia at Canaccord Conference: Strategic Growth in Anemia Treatment By Investing.com - Investing.com Canada
Bollinger Bands Show Potential Breakout in Akebia Therapeutics Inc.July 2025 Fed Impact & Entry Point Confirmation Alerts - beatles.ru
Does Akebia Therapeutics Inc. have declining or rising EPSVerified 200% Stock Tips - thegnnews.com
Is AKBA anticipated to rise today? - AInvest
The Akebia Therapeutics, Inc. (NASDAQ:AKBA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - ca.finance.yahoo.com
Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment? - simplywall.st
How moving averages guide Akebia Therapeutics Inc. tradingIntraday Signal Forecast for Fast Traders - Newser
Identifying reversal signals in Akebia Therapeutics Inc.Free Optimized Watchlist With Daily Adjustments - Newser
What’s next for Akebia Therapeutics Inc. stock priceFree Growth Based Stock Signal Screener - Newser
Akebia outlines access to over 275,000 dialysis patients for Vafseo in Q4 as DaVita pilot launches - MSN
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q2 2025 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics Second Quarter 2025 Earnings: EPS: US$0.001 (vs US$0.041 loss in 2Q 2024) - Yahoo Finance
Akebia Therapeutics Inc. stock trend outlook and recovery pathAsset Growth Pattern and Return Summary - Newser
Akebia Therapeutics (AKBA) Gets a Buy from H.C. Wainwright - The Globe and Mail
What does recent volatility data suggest for Akebia Therapeutics Inc.Free Oversold Bounce Stock Play Ideas - Newser
Akebia Therapeutics Reports Strong Q2 2025 Growth - The Globe and Mail
Using Bollinger Bands to evaluate Akebia Therapeutics Inc.Trend Following Ideas with Volume Confirmation - Newser
Is Akebia Therapeutics Inc. reversing from oversold territoryFree Real Profit Trade Plan Suggestions - Newser
Akebia Therapeutics (AKBA.O) Surges 9.14% — No Technical Signals Fired, But Why? - AInvest
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of “Buy” by Analysts - Defense World
Akebia (AKBA) Prepares for Q2 Earnings Announcement - GuruFocus
Akebia Therapeutics Inc (AKBA) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic ... By GuruFocus - Investing.com Canada
Akebia Therapeutics Inc (AKBA) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives - GuruFocus
Akebia Reports Q2 Vafseo Revenue Growth, Sets Sights on Expanding Access to 275,000 Dialysis Patients - AInvest
Akebia's Q2 2025 Earnings Call: Unpacking Contradictions in Vafseo Trends, Auryxia Revenue, and FDA Strategies - AInvest
Akebia (AKBA) Q2 Revenue Jumps 43% - AOL.com
Akebia Therapeutics shares rise 1.66% after-hours after Q2 revenue beat expectations and Vafseo growth. - AInvest
Akebia Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Akebia Therapeutics Inc (AKBA) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Earnings call transcript: Akebia Ther Q2 2025 earnings miss, stock drops By Investing.com - Investing.com Canada
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2 - Yahoo Finance
Akebia Therapeutics, Inc. SEC 10-Q Report - TradingView
Akebia Therapeutics Q2 revenue smashes expectations - MarketScreener
Akebia Therapeutics Inc Q2 2025 Earnings: Revenue Surges to $62. - GuruFocus
Akebia reports Q2 EPS 0c vs (4c) last year - TipRanks
Akebia Q2 2025: Vafseo net product revenues at $13.3mln, total $60.5mln. - AInvest
Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference - GlobeNewswire
Akebia Q2 2025 Earnings Preview - MSN
Akebia Therapeutics CEO to Discuss Kidney Disease Innovations at Major Growth Conference - Stock Titan
Chart based exit strategy for Akebia Therapeutics Inc.Market Downturn Defense Strategy Analysis - Newser
Akebia Therapeutics Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - MSN
Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT - MSN
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization - GlobeNewswire
Price momentum metrics for Akebia Therapeutics Inc. explainedFree Alpha Focused Technical Trade Signals - Newser
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):